IP Library Granted Patent US 10,676,527
Granted Patent B2
US 10,676,527 · App. 15/893,925 · Granted Jun 9, 2020

Methods and compositions for modulation of blood-neural barrier

Inventors: Ulf Eriksson (Stockholm, SE); Linda Fredriksson (Hagersten, SE); Daniel Lawrence (Ann Arbor, MI); Enming Su (Ann Arbor, MI); Manuel Yepes (Atlanta, GA); Dudley Strickland (Brookville, MD)
Assignees: Ludwig Institute for Cancer Research Ltd.; The Regents of the University of Michigan; University of Maryland, Baltimore
C07K16/2863A61K9/0019A61K31/00A61K38/43A61K39/3955A61K45/06C07K16/22A61K39/39533A61K2039/505C07K2317/24C07K2317/76C12N9/6454
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,676,527
App. No.
15/893,925
Granted
Jun 9, 2020
Kind
B2
Abstract

Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-α antagonist.

Claims (5)

1. A method of treating edema associated with head trauma in a higher vertebrate animal, the method comprising administering to said animal an effective amount of a platelet derived growth factor (PDGF) antagonist or platelet derived growth factor receptor (PDGFR) antagonist, wherein the antagonist is an antibody or a small molecule.

2. The method of claim 1 wherein the animal is a mammal.

3. The method of claim 1 wherein the animal is a human.

4. The method of claim 1 wherein the PDGFR antagonist is imatinib mesylate.

5. The method of claim 1 wherein the edema is associated with traumatic brain injury.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2020
From: STRICKLAND, DUDLEY K.; YEPES, MANUEL S.
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 051683/0445 →
Continuity (7)
Division 15286818 · Oct 6, 2016
Continuation 14282808 · May 20, 2014
Division 13407270 · Feb 28, 2012
Division 11736499 · Apr 17, 2007
Provisional Application 60828506 · Oct 6, 2006
Provisional Application 60792318 · Apr 17, 2006
Related Publication 20180222984A1 · Aug 9, 2018